Pro Medicus Appoints Experienced Investor Relations Leader
Pro Medicus Limited (ASX: PME) has appointed Garry Sherriff as its new Head of Investor Relations, with the appointment taking effect from 20 July 2026. Bringing more than two decades of experience across equity research, investment banking, corporate finance, strategy, and business management, Sherriff has built strong relationships with institutional investors in both Australian and international markets. His appointment is intended to strengthen the company’s engagement with shareholders and the broader investment community as Pro Medicus continues its global growth journey.
Chief Executive Officer Dr Sam Hupert highlighted Sherriff’s extensive knowledge of the technology sector and his previous research coverage of Pro Medicus, noting that this background positions him well to communicate the company’s strategy and long-term vision. Sherriff expressed enthusiasm about joining the business, stating that years of following the company have given him confidence in its leadership, execution, and future growth prospects. He aims to further enhance investor communication while supporting Pro Medicus’ continued focus on creating sustainable long-term value for shareholders and expanding relationships with investors in Australia and overseas.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Pro Medicus Appoints Experienced Investor Relations Leader
Pro Medicus Limited (ASX: PME) has appointed Garry Sherriff as its new Head of Investor Relations, with the appointment taking effect from 20 July 2026. Bringing more than two decades of experience across equity research, investment banking, corporate finance, strategy, and business management, Sherriff has built strong relationships with institutional investors in both Australian and international markets. His appointment is intended to strengthen the company’s engagement with shareholders and the broader investment community as Pro Medicus continues its global growth journey.
Chief Executive Officer Dr Sam Hupert highlighted Sherriff’s extensive knowledge of the technology sector and his previous research coverage of Pro Medicus, noting that this background positions him well to communicate the company’s strategy and long-term vision. Sherriff expressed enthusiasm about joining the business, stating that years of following the company have given him confidence in its leadership, execution, and future growth prospects. He aims to further enhance investor communication while supporting Pro Medicus’ continued focus on creating sustainable long-term value for shareholders and expanding relationships with investors in Australia and overseas.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au